Who is
AMF Medical ?

Advanced Microfluidics SA

Advanced Microfluidics SA (AMF) was founded in 2014 in Lausanne (Switzerland), and remains located on the campus of EPFL, one of Europe’s most vibrant and bright science and technology institutions.

The company’s mission to create next-generation microfluidic automation technologies based on unmet end-user needs has made AMF a go-to partner for research and industry laboratories worldwide.  Inspired by the quest for excellence of Swiss watchmaking, AMF has built a reputation for its ability to create easy-to-use micro-pumps with nanoliter-precision (1 billionth of a liter).  

Even as Advanced Microfluidics’ signature innovations have already become benchmark products, the company continues to push the boundaries of what is technically possible to develop customized solutions.


Over the past decade, microfluidics technology has been at the heart of a paradigm shift in medicine, offering both better metabolic control and a higher quality of life to people with diabetes, thanks to the insulin pump.  

Especially since the arrival of patch pumps, many people with diabetes prefer their ease-of-use and discretion, over traditional multiple-daily injections.  

Located in the heart of the Swiss Medtech Valley, AMF began an Innosuisse-supported project in 2015 to further develop its technology to address unmet needs of patch pump users, followed in 2018 by the actual product development and design of Sigi™, the next-generation plug ‘n go… insulin patch pump. This led then to the creation of AMF Medical SA as a separate company in early 2021.

AMF Medical SA

AMF has been recognized with the SME Instrument ‘Seal of Excellence’ (now EIC Accelerator Award) by the European Innovation Council (EIC) which supports top class innovators, entrepreneurs and small companies with funding opportunities and acceleration services. 

AMF is supported by Canton de Vaud, Innovaud and Innosuisse.

In late 2020, AMF Medical was among the winners of IMD’s annual start-up competition, giving it access to extensive collaboration with MBA students from one of the world’s leading business schools. 

This project has received funding from the European Union’s Horizon 2020 research and innovation programme